Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 390 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung... October 29, 2024 After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms April 11, 2019 ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory... June 16, 2026 GreaterGood’s Inaugural Breast Cancer Research Professor Is Changing the Face of... October 1, 2020 Load more HOT NEWS ESMO Raises Key Issues on Cancer Prevention and Care at the... PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative... FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC... 5 Tips for Managing Financial Stress During Cancer
